Story

Annexon Shares Fall After Key Clinical Trial Protocol Change

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Annexon Shares Fall After Key Clinical Trial Protocol Change
Text size
Background

Shares of Annexon (NASDAQ: ANNX) fell in pre-market trading after the company disclosed a significant amendment to its pivotal late-stage trial for a key drug candidate, prompting investor concern ahead of topline data.

Trial Protocol Amended

Annexon announced it has modified the design of its Phase 3 ARCHER II trial, which is evaluating vonaprument as a treatment for dry age-related macular degeneration with geographic atrophy. The company has added a month 24 co-primary endpoint to the study, supplementing the original primary endpoint at month 15.

Key details of the trial and amendment include:

  • The study, which completed enrollment of 659 patients in July 2025, can now meet its primary objective at either the 15-month or 24-month mark.
  • The primary endpoint measures the proportion of patients who experience a significant loss of vision, defined as a loss of 15 or more letters in best corrected visual acuity at two consecutive visits.

Market Reaction and Investor Concerns

Sample IUX Markets – In-articleAd

The stock dropped 6.4% in pre-open trading on the news. Mid-study changes to a clinical trial's primary endpoints are often viewed negatively by investors, as they can be interpreted as a sign of wavering confidence in the ability to meet the original, earlier goal.

This concern is heightened by the proximity of the trial's topline data readout, which is expected in Q4 2026. This data release represents a pivotal binary event for the company. The stock's decline occurred despite modest gains in the broader S&P 500 and Nasdaq indices, indicating the pressure is company-specific.

Company-Specific Headwinds

Adding to near-term caution is Annexon's upcoming earnings report, scheduled for August 17, 2026, which may be prompting some investors to reduce their exposure. As a clinical-stage company with no product revenue, Annexon relies on equity financing to fund its pipeline.

This financial structure makes its stock particularly sensitive to any news that could alter the perceived risk profile of its lead drug programs. The combination of the trial amendment and the approaching earnings report has created significant downward pressure on the shares.

Read next

More on Stocks
Back to latest news

LATEST